Literature DB >> 18041476

Running promotes wakefulness and increases cataplexy in orexin knockout mice.

Rodrigo A España1, Sarah L McCormack, Takatoshi Mochizuki, Thomas E Scammell.   

Abstract

STUDY
OBJECTIVE: People with narcolepsy and mice lacking orexin/hypocretin have disrupted sleep/wake behavior and reduced physical activity. Our objective was to identify physiologic mechanisms through which orexin deficiency reduces locomotor activity.
DESIGN: We examined spontaneous wheel running activity and its relationship to sleep/wake behavior in wild type (WT) and orexin knockout (KO) mice. Additionally, given that physical activity promotes alertness, we also studied whether orexin deficiency reduces the wake-promoting effects of exercise. MEASUREMENTS AND
RESULTS: Orexin KO mice ran 42% less than WT mice. Their ability to run appeared normal as they initiated running as often as WT mice and ran at normal speeds. However, their running bouts were considerably shorter, and they often had cataplexy or quick transitions into sleep after running. Wheel running increased the total amount of wakefulness in WT and orexin KO mice similarly, however, KO mice continued to have moderately fragmented sleep/wake behavior. Wheel running also doubled the amount of cataplexy by increasing the probability of transitioning into cataplexy.
CONCLUSIONS: Orexin KO mice run significantly less than normal, likely due to sleepiness, imminent cataplexy, or a reduced motivation to run. Orexin is not required for the wake-promoting effects of wheel running given that both WT and KO mice had similar increases in wakefulness with running wheels. In addition, the clear increase in cataplexy with wheel running suggests the possibility that positive emotions or reward can trigger murine cataplexy, similar to that seen in people and dogs with narcolepsy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18041476      PMCID: PMC2082091          DOI: 10.1093/sleep/30.11.1417

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  40 in total

1.  Prior experience with wheel running produces cross-tolerance to the rewarding effect of morphine.

Authors:  Bow Tong Lett; Virginia L Grant; Ming Teng Koh; Gillian Flynn
Journal:  Pharmacol Biochem Behav       Date:  2002-05       Impact factor: 3.533

2.  Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities.

Authors:  Y Yoshida; N Fujiki; T Nakajima; B Ripley; H Matsumura; H Yoneda; E Mignot; S Nishino
Journal:  Eur J Neurosci       Date:  2001-10       Impact factor: 3.386

3.  Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy.

Authors:  Shengwen Zhang; Jamie M Zeitzer; Takeshi Sakurai; Seiji Nishino; Emmanuel Mignot
Journal:  J Physiol       Date:  2007-03-22       Impact factor: 5.182

4.  Fos expression in orexin neurons varies with behavioral state.

Authors:  I V Estabrooke; M T McCarthy; E Ko; T C Chou; R M Chemelli; M Yanagisawa; C B Saper; T E Scammell
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

5.  Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system.

Authors:  T Nakamura; K Uramura; T Nambu; T Yada; K Goto; M Yanagisawa; T Sakurai
Journal:  Brain Res       Date:  2000-08-04       Impact factor: 3.252

6.  Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism.

Authors:  John H Peever; Yuan-Yang Lai; Jerome M Siegel
Journal:  J Neurophysiol       Date:  2003-01-15       Impact factor: 2.714

7.  Delta FosB regulates wheel running.

Authors:  Martin Werme; Chad Messer; Lars Olson; Lauren Gilden; Peter Thorén; Eric J Nestler; Stefan Brené
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

8.  Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins.

Authors:  Tatiana M Korotkova; Olga A Sergeeva; Krister S Eriksson; Helmut L Haas; Ritchie E Brown
Journal:  J Neurosci       Date:  2003-01-01       Impact factor: 6.167

9.  Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.

Authors:  Jon T Willie; Richard M Chemelli; Christopher M Sinton; Shigeru Tokita; S Clay Williams; Yaz Y Kisanuki; Jacob N Marcus; Charlotte Lee; Joel K Elmquist; Kristi A Kohlmeier; Christopher S Leonard; James A Richardson; Robert E Hammer; Masashi Yanagisawa
Journal:  Neuron       Date:  2003-06-05       Impact factor: 17.173

10.  Reduced number of hypocretin neurons in human narcolepsy.

Authors:  T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel
Journal:  Neuron       Date:  2000-09       Impact factor: 17.173

View more
  47 in total

Review 1.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

Review 2.  Sleep neurobiology from a clinical perspective.

Authors:  Rodrigo A España; Thomas E Scammell
Journal:  Sleep       Date:  2011-07-01       Impact factor: 5.849

3.  GABAergic Neurons of the Central Amygdala Promote Cataplexy.

Authors:  Carrie E Mahoney; Lindsay J Agostinelli; Jessica N K Brooks; Bradford B Lowell; Thomas E Scammell
Journal:  J Neurosci       Date:  2017-02-24       Impact factor: 6.167

Review 4.  Animal models of sleep disorders.

Authors:  Linda A Toth; Pavan Bhargava
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

5.  Melanin-concentrating hormone neurons contribute to dysregulation of rapid eye movement sleep in narcolepsy.

Authors:  Fumito Naganuma; Sathyajit S Bandaru; Gianna Absi; Carrie E Mahoney; Thomas E Scammell; Ramalingam Vetrivelan
Journal:  Neurobiol Dis       Date:  2018-08-24       Impact factor: 5.996

6.  GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Tsui-Ming Chen; Andrew K Leung; Jonathan P Wisor; Akihiro Yamanaka; Thomas S Kilduff
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

7.  Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function.

Authors:  Sawako Tabuchi; Tomomi Tsunematsu; Sarah W Black; Makoto Tominaga; Megumi Maruyama; Kazuyo Takagi; Yasuhiko Minokoshi; Takeshi Sakurai; Thomas S Kilduff; Akihiro Yamanaka
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

8.  A consensus definition of cataplexy in mouse models of narcolepsy.

Authors:  Thomas E Scammell; Jon T Willie; Christian Guilleminault; Jerome M Siegel
Journal:  Sleep       Date:  2009-01       Impact factor: 5.849

9.  Elevated sleep quality and orexin receptor mRNA in obesity-resistant rats.

Authors:  V Mavanji; J A Teske; C J Billington; C M Kotz
Journal:  Int J Obes (Lond)       Date:  2010-05-25       Impact factor: 5.095

10.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.